|
| 37870536 | Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. | J Clin Oncol | 2024 |
| 37864520 | Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. | Cancer | 2024 |
| 37758237 | Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors. | Annu Rev Med | 2024 |
| 37793085 | MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. | J Clin Oncol | 2024 |
| 37973647 | Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. | Ann Surg Oncol | 2024 |
| 34789422 | Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. | Eur Urol Oncol | 2023 |
| 37670121 | To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? | Ann Surg Oncol | 2023 |
| 37619847 | HER2-low expression in patients with advanced or metastatic solid tumors. | Ann Oncol | 2023 |
| 37845306 | Molecular tumour boards - current and future considerations for precision oncology. | Nat Rev Clin Oncol | 2023 |
| 37879233 | Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. | ESMO Open | 2023 |
| 38096472 | Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. | JCO Precis Oncol | 2023 |
| 38039429 | Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | JCO Precis Oncol | 2023 |
| 37604642 | T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. | J Immunother Cancer | 2023 |
| 37568622 | A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. | Cancers (Basel) | 2023 |
| 37567892 | Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. | NPJ Breast Cancer | 2023 |
| 37637237 | Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation. | J Immunother Precis Oncol | 2023 |
| 37531248 | The New NCI Precision Medicine Trials. | Clin Cancer Res | 2023 |
| 37058010 | Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). | Clin Cancer Res | 2023 |
| 37454202 | Actionability classification of variants of unknown significance correlates with functional effect. | NPJ Precis Oncol | 2023 |
| 37420274 | Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study. | Mol Cancer Ther | 2023 |
| 37016732 | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. | Cancer | 2023 |
| 37451181 | A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data. | Eur J Cancer | 2023 |
| 37384539 | Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. | Cancer Res | 2023 |
| 37314501 | A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. | Cancer Chemother Pharmacol | 2023 |
| 37309603 | Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. | Clin Cancer Res | 2023 |
| 37279095 | Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. | Clin Cancer Res | 2023 |
| 37339271 | Discordance of HER2 Expression and/or Amplification on Repeat Testing. | Mol Cancer Ther | 2023 |
| 37277454 | Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. | Nat Med | 2023 |
| 37072571 | Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. | NPJ Precis Oncol | 2023 |
| 37068173 | Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. | Cancer Discov | 2023 |
| 37473872 | Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors. | Ann Oncol | 2023 |
| 37129197 | Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. | Cancer | 2023 |
| 37327461 | First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. | J Clin Oncol | 2023 |
| 36751659 | Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. | J Immunother Precis Oncol | 2023 |
| 36653664 | Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. | Ann Surg Oncol | 2023 |
| 36652354 | Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic Cholangiocarcinoma. | N Engl J Med | 2023 |
| 36746967 | Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. | Nat Commun | 2023 |
| 36745260 | ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer. | Ann Surg Oncol | 2023 |
| 36469840 | Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> Amplification. | J Clin Oncol | 2023 |
| 36801912 | BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. | NPJ Precis Oncol | 2023 |
| 36423446 | Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. | Gynecol Oncol | 2023 |
| 36662819 | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). | Clin Cancer Res | 2023 |
| 36631624 | Antibody-drug conjugates in lung cancer: dawn of a new era? | NPJ Precis Oncol | 2023 |
| 36658425 | Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. | Nat Med | 2023 |
| 36200910 | Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. | Oncologist | 2023 |
| 36288393 | Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). | Clin Cancer Res | 2023 |
| 36282874 | Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. | Clin Cancer Res | 2023 |
| 34362693 | Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. | Clin Genitourin Cancer | 2022 |
| 35618285 | Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. | J Immunother Cancer | 2022 |
| 35443062 | Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. | Clin Cancer Res | 2022 |